Prime Medicine, Inc. PRME 深 沪
等待开盘 10-24 09:30:00 美东时间
5.38
+0.270
+5.28%
华盛通- 最 高5.43
- 今 开5.175
- 成交量 270.96万股
- 最 低 4.9999
- 昨 收 5.11
- 总市值 5.08亿
- 52周最高 6.94
- 市盈率 静 --
- 换手率 2.87%
- 52周最低 1.11
- 委 比 89.92%
- 总股本 9433.60万
- 历史最高 21.73
- 量 比 0.68
- 振 幅 8.42%
- 历史最低 1.11
- 每 手 1
- 风险率 1.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | ChowChow上市首日飙升215%；波多黎各签署40亿美元LNG协议，NFE飙涨近45%
ChowChow上市首日飙升215%；波多黎各签署40亿美元LNG协议，NFE飙涨近45%；加密货币挖矿的公司BITF涨超16%，月内累涨超110%>>
09-17 16:39
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index falling over 150 points on Wed...
09-03 22:10
Prime Drink Group Granted Extension for Financial Filings
Dominion Water Reserves ( ($TSE:PRME) ) just unveiled an announcement. Prime Dr...
08-30 10:32
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Prime Medicine Q2 EPS $(0.41) Misses $(0.39) Estimate, Sales $1.115M Beat $750.000K Estimate
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.39) by 6.22 percent. This is a 10.87 percent increase over losses of $(0.46) per share from
08-07 20:09
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates
Prime Medicine reported positive clinical data from its Phase 1/2 trial in Chronic Granulomatous Disease (CGD), demonstrating early efficacy and safety of Prime Editing. The company secured $144.2 million from a follow-on offering and up to $24 million from the Cystic Fibrosis Foundation to advance its pipeline. Allan Reine, M.D., was appointed CEO, leading a strategic restructuring to enhance operational efficiency. The company expects its cash ...
08-07 12:00
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Prime Medicine, a biotechnology company, closed an underwritten public offering of 43.7 million shares at $3.30 per share, raising approximately $144.2 million. The offering included the full exercise of the underwriters’ option to purchase additional shares and utilized an effective shelf registration statement. The funds will support the company’s efforts in developing gene editing therapies using its Prime Editing platform.
08-01 20:01
Prime Medicine slides after pricing $125.4M stock offering
Prime Medicine (NASDAQ:PRME) has priced its public offering of 38 million shares at $3.30 each, aiming to raise about $125.4 million before expenses. The company has also given underwriters a 30-day o...
07-31 11:51
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers OSR Holdings (NASDAQ:OSRH) stock rose 21.4% to $1.05 during Wednesday'...
07-31 05:06
Prime Medicine Halts Sales Agreement Prospectus
Prime Medicine, Inc. ( ($PRME) ) has provided an update. On July 30, 2025, Prim...
07-31 04:50
